In controls, metformin showed minor growth-inhibiting effects on the four breast cancer cell lines (3.6 ± 1.4% inhibition) but higher inhibition on the proliferation of HIP2, KM76 and W59 BM-MSCs (12.3 ± 2.2% inhibition). Here, UBE2K is linked to breast carcinoma.